Arcellx (ACLX) Other Non-Current Assets (2021 - 2025)
Arcellx's quarterly Other Non-Current Assets came in at $3.0 million in Q4 2025, up 179.29% year-on-year from $1.1 million in Q4 2024, and up 814.29% quarter-over-quarter from $329000.0 in Q3 2025.
Arcellx has reported Other Non-Current Assets for 5 years, with the latest figure at $3.0 million in Q4 2025.
- For the quarter ending Q4 2025, Other Non-Current Assets rose 179.29% year-over-year to $3.0 million; the trailing twelve-month figure through Dec 2025 stood at $3.0 million (up 179.29% YoY), and the FY2025 full-year result was $3.0 million, up 179.29% from the prior year.
- Other Non-Current Assets for Q4 2025 stood at $3.0 million, up from $329000.0 in the prior quarter.
- The five-year high for Other Non-Current Assets was $9.4 million in Q4 2023, with the low at $199000.0 in Q1 2022.
- Average Other Non-Current Assets over 5 years is $2.6 million, with a median of $2.5 million recorded in 2022.
- Year-over-year, Other Non-Current Assets soared 1156.78% in 2023 and sank 88.49% in 2024.
- Tracing ACLX's Other Non-Current Assets over 5 years: stood at $3.2 million in 2021, then slipped by 21.15% to $2.5 million in 2022, then surged by 274.09% to $9.4 million in 2023, then slumped by 88.49% to $1.1 million in 2024, then soared by 179.29% to $3.0 million in 2025.
- The last three Other Non-Current Assets figures came in at $3.0 million (Q4 2025), $329000.0 (Q3 2025), and $2.4 million (Q2 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Other Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | 12.40 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | 60,000.00 |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 1.26 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 2.13 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 63.55 Mn |
| 10 | Arcellx | 6.48 Bn | 6.48 Bn | - | 3.01 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 3.01 Mn |
| Sep 30, 2025 | 329,000.00 |
| Jun 30, 2025 | 2.42 Mn |
| Mar 31, 2025 | 2.42 Mn |
| Dec 31, 2024 | 1.08 Mn |
| Sep 30, 2024 | 1.33 Mn |
| Jun 30, 2024 | 1.22 Mn |
| Mar 31, 2024 | 2.42 Mn |
| Dec 31, 2023 | 9.36 Mn |
| Sep 30, 2023 | 4.93 Mn |
| Jun 30, 2023 | 2.50 Mn |
| Mar 31, 2023 | 2.50 Mn |
| Dec 31, 2022 | 2.50 Mn |
| Sep 30, 2022 | 2.50 Mn |
| Jun 30, 2022 | 2.50 Mn |
| Mar 31, 2022 | 199,000.00 |
| Dec 31, 2021 | 3.17 Mn |